Loading
Rise Therapeutics
Rise Therapeutics develops oral immune treatments. Its cancer medicine, R-5780, is a pill meant to help checkpoint immunotherapy work in tumours that have not responded to it, and it is in an early trial.
Also called: Rise Therapeutics, LLCRise Therapeutics LLC
Overview
Rise Therapeutics develops oral immunotherapies with its own oral delivery platform and in-house GMP manufacturing, for autoimmune disease and cancer. Its oncology product R-5780 is designed to enhance immune checkpoint inhibitor activity; the NIH RePORTER abstract describes it as based on secreted antigen A (SagA), an enzyme from Enterococcus faecium that engages microbiome-associated immune pathways. R-5780 is in a phase 1 trial with PD-1 inhibitors in solid tumours (NCT06398418). In fiscal year 2026 NCI awarded the company USD 740,140 under SBIR award 1R44CA306440-01A1 for clinical validation of R-5780.
Headquarters
Rockville, MD, US
Scorecard
All companies#738of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 1R44CA306440-01A1: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors | 2026 | $740K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 1Oral microbial immunotherapy
R-5780 is an experimental pill from Rise Therapeutics designed to help immunotherapy drugs work in tumours that resist them. It is in an early trial with PD-1 inhibitors.
Notes
- The website also lists autoimmune programmes, not recorded here. Read on risetherapeutics.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026.
Connected
3fronts
technologies
drugs
Phase 1Oral microbial immunotherapy
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
risetherapeutics.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/